NCT02195973View on ClinicalTrials.gov

Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

December 10, 2016

Study Completion Date

September 30, 2017

Conditions
Recurrent Ovarian Cancer
Interventions
DRUG

LDE225

After six cycles of weekly paclitaxel and LDE225, patients with a clinically beneficial response may be continued on weekly paclitaxel alone until disease progression.

Trial Locations (1)

35294

University of Alabama at Birmingham, Birmingham

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

University of Alabama at Birmingham

OTHER